Heart failure-induced skeletal myopathy in spontaneously hypertensive rats  by Damatto, R.L. et al.
International Journal of Cardiology 167 (2013) 698–703
Contents lists available at SciVerse ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdHeart failure-induced skeletal myopathy in spontaneously hypertensive rats☆
R.L. Damatto a,b, P.F. Martinez a,b, A.R.R. Lima a,b, M.D.M. Cezar a,b, D.H.S. Campos a,b, S.A. Oliveira Junior a,b,c,
D.M. Guizoni a,b, C. Bonomo a,b, B.T. Nakatani a,b, M. Dal Pai Silva d,e, R.F. Carvalho d,e,
K. Okoshi a,b, M.P. Okoshi a,b,⁎
a Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Brazil
b Departamento de Clinica Medica, Faculdade de Medicina de Botucatu, Rubiao Junior, S/N 18618 970, Botucatu, SP, Brazil
c Federal University of Mato Grosso do Sul, Campo Grande, Brazil
d Department of Morphology, Institute of Biosciences, Sao Paulo State University, UNESP, Brazil
e Departamento de Morfologia, Instituto de Biociencias, Rubiao Junior S/N, Botucatu, SP, Brazil☆ Grants: Financial support was provided by CNPq
2009-5), FAPESP (2009/54857-4, 2009/54102, and 20
(01197/08).
⁎ Corresponding author at: Departamento de Clinica M
de Botucatu, UNESP, Rubiao Junior, S/N 18618-970, Bot
3882 2969; fax: +55 14 3882 2238.
E-mail address: mpoliti@fmb.unesp.br (M.P. Okoshi)
0167-5273/$ – see front matter © 2012 Elsevier Ireland
doi:10.1016/j.ijcard.2012.03.063a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 December 2011
Received in revised form 2 March 2012
Accepted 3 March 2012








Background: Although skeletal muscle atrophy and changes inmyosin heavy chain (MyHC) isoforms have often
been observed during heart failure, their pathophysiological mechanisms are not completely deﬁned. In this
study we tested the hypothesis that skeletal muscle phenotype changes are related to myogenic regulatory
factors and myostatin/follistatin expression in spontaneously hypertensive rats (SHR) with heart failure.
Methods: After developing tachypnea, SHR were subjected to transthoracic echocardiogram. Pathological
evidence of heart failure was assessed during euthanasia. Age-matched Wistar–Kyoto (WKY) rats were used
as controls. Soleus muscle morphometry was analyzed in histological sections, and MyHC isoforms evaluated
by electrophoresis. Protein levels were assessed by Western blotting. Statistical analysis: Student's t test and
Pearson correlation.
Results: All SHR presented right ventricular hypertrophy and seven had pleuropericardial effusion. Echocardio-
graphic evaluation showed dilation in the left chambers and left ventricular hypertrophy with systolic and
diastolic dysfunction in SHR. Soleus weight and ﬁber cross sectional areas were lower (WKY 3615±412; SHR
2035±224 μm2; Pb0.001), and collagen fractional volume was higher in SHR. The relative amount of type I
MyHC isoform was increased in SHR. Myogenin, myostatin, and follistatin expression was lower and MRF4
levels higher in SHR. Myogenin and follistatin expression positively correlated with ﬁber cross sectional areas
and MRF4 levels positively correlated with I MyHC isoform.
Conclusion: Reduced myogenin and follistatin expression seems to participate in muscle atrophy while in-
creased MRF4 protein levels canmodulate myosin heavy chain isoform shift in skeletal muscle of spontaneously
hypertensive rats with heart failure.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Heart failure is characterized by reduced exercise tolerance with
early occurrence of fatigue and dyspnea. In addition to cardiac
dysfunction and pulmonary abnormalities, intrinsic skeletal muscle
changes can be involved in reduced physical capacity [1–4]. Several
skeletal muscle abnormalities have been described in patients and
animals with heart failure; these include atrophy, ﬁbrosis, altered(305013/2009-0 and 304998/
10/50461-6) and Fundunesp
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.
Ltd. All rights reserved.myosin heavy chain (MyHC) composition, and decreased oxidative
capacity [1,2,5–9].
The mechanisms and intracellular signaling pathways involved in
heart failure-induced skeletal muscle abnormalities are not complete-
ly understood. There is substantial evidence that myogenic regulatory
factors (MRF) MyoD, myogenin, Myf5, and MRF4 act as important
regulators of muscle protein expression [10–12]. MRFs are transcrip-
tional factors that activate the expression of muscle speciﬁc genes.
Myogenin is preferentially expressed in slow twitch ﬁbers and
modulates the expression of oxidative enzymes [13]. MyoD, which
is preferentially expressed in fast muscle ﬁbers, participates in muscle
regeneration [11,14]. MRF4 may play a role in preserving differentiat-
ed muscle state [15]. Few studies have evaluated MRFs during
heart failure. Our laboratory has observed decreased mRNA levels
for MyoD and MRF4 in soleus muscle of rats with rapid onset
heart failure [16] while rats with chronic heart failure presented
decreased myogenin protein levels [5].
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superfamily, modulates muscle growth, acting as a negative regulator
of skeletal muscle mass [17,18]. Studies on its physiological role have
shown a negative correlation between myostatin gene expression and
muscle mass, suggesting a potential to induce skeletal muscle atrophy
[17,19,20]. Myostatin activity can be modulated by various proteins.
Follistatin has emerged as a potent myostatin antagonist which acts
by modifying its in vivo activity [21–23]. Few authors have assessed
the myostatin/follistatin pathway in heart failure [6,24]. In our
laboratory, rats with myocardial infarction-induced heart failure
presented muscle atrophy in combination with unchanged myostatin
levels and decreased follistatin protein expression [6].
One widely used experimental model for studying heart failure is
the spontaneously hypertensive rat (SHR). It presents early arterial
hypertension and left ventricular hypertrophy which evolves to
heart failure during maturity and senescence. As cardiac failure
development is slow, SHRs are considered a useful model to mimic
clinical heart failure settings. In this study we characterized skeletal
muscle changes of SHR with heart failure by evaluating muscle
trophism, ﬁbrosis, and myosin heavy chain isoforms. We tested the
hypothesis that heart failure-induced skeletal muscle phenotype
changes are related to myogenic regulatory factors and myostatin/
follistatin protein expression changes.2. Materials and methods
2.1. Experimental groups
Male spontaneously hypertensive rats (SHR) and non-hypertensive Wistar–Kyoto
(WKY) rats were purchased from the Central Animal House at Botucatu Medical
School, UNESP. All animals were housed in a room under temperature control at
23 °C and kept on a 12-hour light/dark cycle. Food and water were supplied ad libitum.
All experiments and procedures were approved by the Ethics Committee of Botucatu
Medical School, UNESP, Botucatu, SP, Brazil.
Systolic arterial pressure was measured by the tail-cuff method at ﬁfteenmonths of
age. Beginning at 18 months old, all rats were observed twice weekly to identify clinical
heart failure features. Animalswere studied after heart failure had been detected, which
was characterized by tachypnea and labored respiration. Age matched WKY rats were
studied at comparable ages. After diagnosing heart failure, rats were subjected to
transthoracic echocardiography and euthanized two days after. During euthanasia, we
evaluated pathological evidence of heart failure such as pleuropericardial effusion, left
atrial thrombi, ascites, pulmonary congestion (lung weight-to-body weight ratio>2
standard deviations above the mean for the WKY group) [25], and right ventricular
hypertrophy (right ventricle weight-to-body weight ratio>0.8 mg/g) [26–29].
At the time of euthanasia, the animals were weighed, anesthetized with
intraperitoneal sodium pentobarbital (50 mg/kg), and decapitated. The heart was
removed by thoracotomy and the atria and ventricles were separated and weighed.
Both right and left soleus muscles were excised, weighed, immediately frozen in liquid
nitrogen, and stored at −80 °C. Fragments of liver were weighed before and after
drying sessions (65 °C for 72 h) to evaluate wet/dry weight ratio.2.2. Echocardiographic study
Echocardiographic evaluation was performed using a commercially available
echocardiograph (General Electric Medical Systems, Vivid S6, Tirat Carmel, Israel)
equipped with a 5–11.5 MHz multifrequency transducer. Rats were anesthetized
by intramuscular injection of a mixture of ketamine (50 mg/kg) and xylazine
(0.5 mg/kg). A two-dimensional parasternal short-axis view of the left ventricle (LV)
was obtained at the level of the papillary muscles. M-mode tracings were obtained
from short-axis views of the LV at or just below the tip of the mitral-valve leaﬂets,
and at the level of the aortic valve and left atrium [29,30]. M-mode images of the LV
were printed on a black-and-white thermal printer (Sony UP-890MD) at a sweep
speed of 100 mm/s. All LV structures were manually measured by the same observer
according to the leading-edge method of the American Society of Echocardiography
[31]. The measurements obtained were the mean of at least ﬁve cardiac cycles on the
M-mode tracings. The following structural variables were measured: left atrium (LA)
diameter, LV diastolic and systolic dimensions (LVDD and LVSD, respectively), LV
diastolic posterior wall thickness (PWT), LV diastolic septal wall thickness (SWT),
and aortic diameter (AO). Left ventricular function was assessed by the following
parameters: heart rate (HR), endocardial fractional shortening (FS), LV ejection
fraction (EF), posterior wall shortening velocity (PWSV), early-to-late diastolic mitral
inﬂow ratio (E/A ratio), E-wave deceleration time (EDT), and isovolumetric relaxation
time (IVRT).2.3. Morphologic study
Serial transverse sections of the soleus muscles were cut at 8 μm thickness in a
cryostat cooled to −20 °C and stained with hematoxylin and eosin. At least 150
cross-sectional ﬁber areas were measured from each soleus muscle. Other slides
were stained with Sirius Red F3BA and used to quantify interstitial collagen fraction
[32]. On average, 20 microscopic ﬁelds were analyzed with a 40X lens. Perivascular
collagen was excluded from this analysis. Measurements were taking using a
compound microscope (Leica DM LS; Nussloch, Germany) attached to a computerized
imaging analysis system (Media Cybernetics, Silver Spring, MD, USA).
2.4. Myosin heavy chain (MyHC) isoforms
MyHC isoform analysis was performed in duplicate by sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE). Frozen samples of soleus muscle
(100 mg) were mechanically homogenized on ice in 0.8 mL of protein extraction
solution containing 50 mM phosphate potassium buffer (pH 7.0), 0.3 M sucrose,
0.5 mM dithiotreitol (DTT), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.3 mM
phenylmetylsulphonyl ﬂuoride (PMSF), 10 mM sodium ﬂuoride and protease inhibitor
cocktail (Sigma, St. Louis, MO, USA). Homogenates were centrifuged at 12,000×g at
4 °C for 20 min to remove insoluble tissue. Total protein quantiﬁcation was performed
in supernatant aliquots by the Bradford method. Samples were then diluted to a ﬁnal
concentration of 1 μg of protein/μL in a solution containing 65% (vol/vol) glycerol,
2.5% (vol/vol) 2-mercaptoethanol, 1.15% (wt/vol) SDS, and 0.45% (wt/vol) Tris–HCl
(pH 6.8). Small amounts of the diluted extracts (15 μL) were loaded onto a 7–10%
SDS-PAGE separating gel with a 4% stacking gel, run overnight (24–30 h) at 120 V,
and stained with Coomassie blue. Two MyHC isoforms, MyHC I and MyHC IIa, were
identiﬁed according to the molecular mass and quantiﬁed by densitometry. Their
relative amounts were expressed as the percentage of the total amount of myosin
heavy chain.
2.5. Western blotting analysis
Protein levels of soleus muscle were analyzed by Western blotting according to a
previously described method [33,34] with speciﬁc anti-myogenin (M-225, sc-576),
anti-MyoD (M-318, sc-760), anti-MRF4 (C-19, sc-301), anti-myostatin (N-19-R
sc-6885-R) or anti-follistatin (H-114 sc-30194) antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Protein levels were normalized to those of GAPDH (6 C5,
sc-32233, Santa Cruz Biotechnology). Muscle protein was extracted using Tris-Triton
buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
10% glycerol, 0.1% SDS, 0.5% deoxycholate). Supernatant protein content was
quantiﬁed by the Bradford method. Samples were separated on a polyacrylamide gel
and then transferred to a nitrocellulose membrane. After blockage, membrane was
incubated with the primary antibody. Membrane was washed with TBS and Tween
20 and incubated with secondary peroxidase-conjugated antibody. Super Signal®
West Pico Chemiluminescent Substrate (Pierce Protein Research Products, Rockford,
USA) was used to detect bound antibodies.
2.6. Statistical analysis
Data are expressed as mean±standard deviation. Comparisons between the
groups were performed by Student's-t test. Associations between variables were
assessed with Pearson's correlation coefﬁcient. The level of signiﬁcance was set at 5%.
3. Results
3.1. Group characterization and anatomic parameters
In SHR (n=8), all rats presented right ventricular hypertrophy, 7
had pleuropericadial effusion, 5 pulmonary congestion, 4 atrial
thrombi, and 3 ascites. There was no clinical or pathological evidence
of heart failure in WKY (n=9). Blood pressure and anatomical data
are shown in Table 1. Blood pressure was higher and body weight
lower in SHR. LV, right ventricle, and atria weight, in both absolute
or body weight normalized values, were greater in SHR than WKY.
Liver wet weight-to-dry weight, lung weight, and lung-to-body
weight ratio were higher in SHR. Soleus weight was lower in SHR
(WKY 0.157±0.029; SHR 0.129±0.021 g; P=0.044).
3.2. Echocardiographic evaluation
Structural cardiac parameters are shown in Table 2. LV diastolic
diameter (LVDD) and left atrium diameter-to-aortic diameter ratio
were similar between groups. LVDD-to-body weight ratio, LV systolic
diameter, LV diastolic posterior wall thickness, LV diastolic septal wall
Table 1
Blood pressure and anatomic data.
WKY (n=9) SHR (n=8) P value
BP (mmHg) 118±10 221±35 b0.001
BW (g) 414±57 295±29 b0.001
LV weight (g) 0.80±0.14 1.18±0.24 b0.001
RV weight (g) 0.26±0.04 0.50±0.13 b0.001
Atria (g) 0.097±0.018 0.243±0.078 b0.001
LV weight/BW (mg/g) 1.94±0.24 3.97±0.49 b0.001
RV weight/BW (mg/g) 0.62±0.08 1.70±0.35 b0.001
Atria/BW (mg/g) 0.27±0.05 0.82±0.21 b0.001
Liver wet/dry 3.28±0.07 3.53±0.27 0.016
Lung (g) 2.32±0.39 3.65±1.0 0.002
Lung/BW (mg/g) 5.67±1.13 12.39±3.35 b0.001
WKY: normotensive rats; SHR: spontaneously hypertensive rats; n: number of animals;
BP: systolic blood pressure; BW: body weight; LV: left ventricle; RV: right ventricle.
Data are expressed as the mean±standard deviation. Student's-t test.
Table 3
Left ventricular functional data.
WKY (n=9) SHR (n=6) P value
HR (bpm) 253±42 304±21 0.016
FS (%) 54.6±6.3 42.2±7.1 0.003
EF 0.90±0.04 0.80±0.08 0.004
PWSV (mm/s) 32.9±4.1 30.2±4.9 0.256
E Wave (cm/s) 78.1±14.1 71.7±16.8 0.435
A Wave (cm/s) 45.0±11.8 62.5±25.4 0.091
E/A 1.83±0.49 1.58±1.48 0.639
ETD (ms) 44.3±9.04 40.5±14.9 0.646
IVRT (ms) 33.7±4.18 38.0±3.09 0.049
WKY: normotensive rats; SHR: spontaneously hypertensive rats; n: number of
animals; HR: heart rate; FS: endocardial fractional shortening; EF: ejection fraction;
PWSV: posterior wall shortening velocity; E/A: early-to-late diastolic mitral inﬂow
ratio; EDT: E-wave deceleration time; IVRT: isovolumetric relaxation time. Data are
expressed as the mean±standard deviation. Student's-t test.
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diameter-to-body weight ratio were higher in SHR than WKY.
Functional LV assessment results are shown in Table 3. Endocardial
fractional shortening and LV ejection fraction were lower in SHR. Heart
rate and isovolumic relaxation time were higher in SHR than WKY.
Posterior wall shortening velocity, mitral A wave, mitral E wave, E/A
ratio, and deceleration time of mitral E wave were not different
between groups.
3.3. Morphologic study
Fiber cross sectional areas were lower (WKY 3.615±412; SHR
2.035±224 μm2; Pb0.001; Fig. 1), and collagen fractional area was
higher (WKY 2.61±0.39; SHR 4.88±0.98%; Pb0.001) in SHR.
3.4. Myosin heavy chain (MyHC) isoforms
The relative amount of the MyHC I isoformwas higher in SHR than
WKY (WKY 80.4±3.33%; SHR 91.2±3.33%; P=0.003; Fig. 2).
3.5. Western blotting analysis
Myogenin protein levels were lower and MRF4 levels were higher
in SHR (myogenin: WKY 1.00±0.16; SHR 0.64±0.35 arbitrary units;
P=0.02; MRF4: WKY 1.00±0.27; SHR 1.53±0.47 arbitrary units;
P=0.014; Fig. 3). MyoD was not statistically different between
groups (WKY 1.00±0.16; SHR 0.89±0.22 arbitrary units; P=0.29;
Fig. 3). Myostatin and follistatin protein levels were lower in SHR
(myostatin: WKY 1.00±0.18; SHR 0.69±0.24 arbitrary units;
P=0.01; follistatin: WKY 1.00±0.17; SHR 0.65±0.16 arbitrary
units; P=0.001; Fig. 4). The myostatin-to-follistatin expression ratio
did not differ between groups (P>0.05). Myogenin levels positivelyTable 2
Echocardiographic data.
WKY (n=9) SHR (n=6) P value
LVDD (mm) 8.01±0.95 8.64±1.46 0.330
LVDD/BW (mm/kg) 19.6±3.1 27.7±4.7 0.001
LVSD (mm) 3.68±0.92 5.08±1.51 0.043
PWT (mm) 1.47±0.06 1.82±0.15 b0.001
SWT (mm) 1.49±0.05 1.82±0.15 b0.001
AO (mm) 4.49±0.38 4.98±0.34 0.024
LA (mm) 5.73±0.59 7.28±1.17 0.004
LA/AO 1.29±0.19 1.47±0.26 0.139
LA/BW (mm/kg) 13.9±0.89 23.3±3.43 b0.001
WKY: normotensive rats; SHR: spontaneously hypertensive rats; n: number of animals;
LVDD and LVSD: left ventricle (LV) diastolic and systolic diameters, respectively;
BW: body weight; PWT: LV diastolic posterior wall thickness; SWT: diastolic septal
wall thickness; AO: aortic diameter; LA: left atrium diameter. Data are expressed as the
mean±standard deviation. Student's-t test.correlated with myocyte cross sectional area (r=0.55; P=0.033).
MRF4 levels were positively correlated with relative amount of
MyHC isoform I (r=0.622; P=0.013); there was a trend for MRF4
levels to negatively correlate with myocyte cross sectional area (r=
−0.45; P=0.08).
4. Discussion
In this study,we showed that heart failure-induced skeletalmyopathy
in spontaneously hypertensive rats is characterized by atrophy, ﬁbrosis,
and changed myosin heavy chain isoforms. Phenotypical muscle
alterations are combinedwithmyogenic regulatory factors andmyostatin
and follistatin protein expression changes.
To the best of our knowledge, this is the ﬁrst study to evaluate
skeletal muscle in SHR with heart failure. The spontaneously
hypertensive rat was introduced by Okamoto and Aoki as a genetic
model of arterial hypertension [35]. Beginning at 18 months of age,
rats develop heart failure features and evolve to death usually withinFig. 1. Transverse histological sections of skeletal muscle soleus stained with
hematoxylin-eosin. A: Wistar Kyoto rat; B: spontaneously hypertensive rat (SHR).
Objetive: 40×.
Fig. 2. Relative amount of myosin heavy chain (MyHC) I isoform of skeletal soleus
muscle analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis.
Data are expressed as mean±standard deviation; * P=0.003.
Fig. 4. Protein expression of myostatin and follistatin in soleus muscle analysed by
Western blot (n=8). Data expressed as mean±standard deviation; * P=0.01;
# P=0.001.
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based on the presence of tachypnea and labored respiration and
conﬁrmed by pathological post mortem ﬁndings such as right
ventricular hypertrophy, pleuropericardial effusion, pulmonary
congestion, left atrial thrombus, and ascites. Systemic congestion was
conﬁrmed by the increased liver wet weight-to-dry weight ratio in
the SHR group. Transthoracic echocardiography showed that SHR
presented dilation of the left cardiac chambers, LV wall hypertrophy,
and LV systolic dysfunction.
Skeletal muscle evaluation was performed in the soleus muscle,
a muscle susceptible to acute and chronic heart failure conditions
[7,36,37]. SHR presented signiﬁcant muscle atrophy characterized
by a 43.7% decrease in average muscle ﬁber cross sectional area
compared to WKY. Decreased muscle ﬁber cross sectional area or
diameter has been commonly observed in experimental heart failure,
reducing between 9.7% and 16.5% from control values [6,7,16,38]. The
signiﬁcant degree of atrophy observed in SHR makes it particularly
useful in studies for identifying the mechanisms and intracellular
signaling pathways involved in heart failure-induced muscle atrophy.
Changes of skeletal MyHC isoform distribution have frequently
been described during cardiac failure. In this study we found a
relative increase of MyHC I isoform in SHR, suggesting a shift of
muscle phenotype toward type I slow ﬁbers, which have a predomi-
nantly oxidative metabolism [39]. During heart failure, other studies
have reported both preserved MyHCs distribution [4,40] and increased
MyHC II isoform [7,36,41,42], which contrast with our results. SixFig. 3. Protein expression of myogenin, MyoD, and MRF4 in soleus muscle analysed by Westmonth-old SHRs have shown decreased MyHC I compared to
age-matched WKY rats [43]. The variety of MyHC isoform distribution
values seen during heart failure suggests that the molecular
mechanisms involved in MyHC isoform modulation differ according
to the heart failure model used [5,7,44].
We evaluated myogenic regulatory factors and myostatin/follistatin
protein expression as potential mechanisms responsible for muscle
atrophy andMyHC isoform changes.We observed decreasedmyogenin,
myostatin, and follistatin; increased MRF4; and unchanged MyoD
protein levels in the SHR group.
Myogenin is involved in satellite cells differentiation and myotube
formation [13,45]. Decreased myogenin expression impairs ﬁber
regeneration and may thus contribute to muscle atrophy [46]. In our
study, decreased myogenin expression in SHR and a positive
correlation between ﬁber cross-sectional area and myogenin levels
suggest that this myogenic regulatory factor is involved in muscle
atrophy. A similar result has been observed in the soleus muscle of
rats with myocardial infarction-induced heart failure [5]. Myogenin
is predominantly related to oxidative metabolism; one would
therefore expect its reduced expression to have induced a decrease
in type I MyHC isoform. However, we found increased type I MyHC
isoform in SHR. As we evaluated the proportion of MyHCs isoforms
in relation to total MyHC, we cannot rule out the possibility of a
reduction in absolute amount of type I isoform. The mechanisms
involved in myogenin reduction during heart failure are not
completely understood. In cell culture, myogenin expression isern blot (n=8). Data expressed as mean±standard deviation; * P=0.02; # P=0.014.
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necrosis factor-α, a cytokine which commonly increases during
heart failure [46].
Myogenic regulatory factor MRF4 is predominantly expressed in
slow oxidative ﬁbers, and appears to play a role in modulating muscle
phenotype. In this study, increased MRF4 protein expression in SHR
was probably involved in the increased percentage of predominantly
oxidative type I MyHC isoforms. Reinforcing this hypothesis, we
observed a positive correlation between MRF4 protein expression
and the relative amount of MyHC isoform I. The mechanisms
responsible for changes in MRF4 expression are not clear. Myostatin-
deﬁcient double-muscled Japanese Shorthorn cattle exhibit increased
MRF4 gene expression [47], suggesting that the decreased myostatin
levels in our study may have played a role in increased MRF4
expression.
Increased myostatin expression has often been associated with
reduced muscle mass in chronic diseases [48,49] and experimental
muscle atrophy models [17,50]. Therefore, it was surprising to ﬁnd
decreased myostatin expression combined with signiﬁcant muscle
atrophy in our SHR group. Myostatin activity can be modulated by
various proteins. One of the most studied myostatin antagonists is
follistatin [21–23,51]. When administered to rats with portosystemic
shunting, it resulted in increased muscle weight and lean body mass
[52]. It has also been suggested that follistatin decreases skeletal
muscle ﬁbrosis and improves muscle healing after injury and disease
[53,54]. Reduced follistatin levels in our study may have contributed
to muscle ﬁbrosis and atrophy despite reduced myostatin expression
in the SHR group. Additionally, as follistatin can increase myogenin
expression in cell culture preparations [53], its decreased levels
could be involved in down-regulating myogenin in the SHR
group. Few authors have investigated the myostatin pathway in
cardiac failure [6,24]. Lenk et al. [24] observed that following
experimental myocardial infarction, myostatin was up-regulated in
gastrocnemius muscle, with values returning to baseline levels after
exercise training. We previously observed that rats with long-term
myocardial infarction-induced heart failure present muscle atrophy
in combination with unchanged myostatin levels and decreased
follistatin protein expression [6]. Additional studies are needed to
better elucidate the relationship between myogenic regulatory
factors, myostatin and the follistatin pathway, and muscle phenotype
changes during heart failure.
In conclusion, heart failure-induced skeletal myopathy of sponta-
neously hypertensive rats is characterized by atrophy, ﬁbrosis, and
changed myosin heavy chain isoforms. Reduced myogenin and follis-
tatin protein expression seems to participate in muscle atrophy while
increased MRF4 protein expression can modulate myosin heavy chain
isoform shift in the soleus muscle.Acknowledgments
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